Mirum Pharmaceuticals, Inc. (FRA:08D)

Mirum Pharmaceuticals Statistics

Total Valuation

FRA:08D has a market cap or net worth of EUR 3.10 billion. The enterprise value is 3.05 billion.

Market Cap	3.10B
Enterprise Value	3.05B

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	51.39M
Shares Outstanding	n/a
Shares Change (YoY)	+4.69%
Shares Change (QoQ)	+14.61%
Owned by Insiders (%)	1.41%
Owned by Institutions (%)	99.28%
Float	43.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.70
PB Ratio	12.43
P/TBV Ratio	60.37
P/FCF Ratio	81.94
P/OCF Ratio	81.25
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-86.28
EV / Sales	7.51
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	80.65

Financial Position

The company has a current ratio of 3.31, with a Debt / Equity ratio of 1.09.

Current Ratio	3.31
Quick Ratio	3.01
Debt / Equity	1.09
Debt / EBITDA	n/a
Debt / FCF	7.19
Interest Coverage	-2.91

Financial Efficiency

Return on equity (ROE) is -15.81% and return on invested capital (ROIC) is -4.50%.

Return on Equity (ROE)	-15.81%
Return on Assets (ROA)	-3.60%
Return on Invested Capital (ROIC)	-4.50%
Return on Capital Employed (ROCE)	-6.69%
Revenue Per Employee	1.13M
Profits Per Employee	-99,450
Employee Count	322
Asset Turnover	0.65
Inventory Turnover	4.15

Taxes

In the past 12 months, FRA:08D has paid 505,414 in taxes.

Income Tax	505,414
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.51% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+41.51%
50-Day Moving Average	59.95
200-Day Moving Average	48.32
Relative Strength Index (RSI)	55.30
Average Volume (20 Days)	1

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	11.99

Income Statement

In the last 12 months, FRA:08D had revenue of EUR 402.11 million and -35.30 million in losses. Loss per share was -0.72.

Revenue	402.11M
Gross Profit	321.35M
Operating Income	-35.62M
Pretax Income	-34.80M
Net Income	-35.30M
EBITDA	-14.97M
EBIT	-35.62M
Loss Per Share	-0.72

Balance Sheet

The company has 320.08 million in cash and 271.68 million in debt, giving a net cash position of 48.40 million.

Cash & Cash Equivalents	320.08M
Total Debt	271.68M
Net Cash	48.40M
Net Cash Per Share	n/a
Equity (Book Value)	248.91M
Book Value Per Share	4.85
Working Capital	315.54M

Cash Flow

In the last 12 months, operating cash flow was 38.09 million and capital expenditures -318,760, giving a free cash flow of 37.77 million.

Operating Cash Flow	38.09M
Capital Expenditures	-318,760
Free Cash Flow	37.77M
FCF Per Share	n/a

Margins

Gross margin is 79.92%, with operating and profit margins of -8.86% and -8.78%.

Gross Margin	79.92%
Operating Margin	-8.86%
Pretax Margin	-8.65%
Profit Margin	-8.78%
EBITDA Margin	-3.72%
EBIT Margin	-8.86%
FCF Margin	9.39%

Dividends & Yields

FRA:08D does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.69%
Shareholder Yield	-4.69%
Earnings Yield	-1.14%
FCF Yield	1.22%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:08D has an Altman Z-Score of 2.75 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.75
Piotroski F-Score	4